Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

Interleukin-6: a new therapeutic target in systemic sclerosis?
Clinical & Translational Immunology ^ | 12 April 2013 | Steven O'Reilly, Rachel Cant, Marzena Ciechomska and Jacob M van Laar

Posted on 05/08/2013 3:50:30 PM PDT by neverdem

Abstract

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells, except lymphocytes and hepatocytes, express the functional membrane IL-6 receptor thus reducing the number of IL-6-responsive cells. Trans-signalling, the shedding of the membrane-bound form of the IL-6 receptor into the local microenvironment, greatly increases the range of cells that can respond. IL-6 has been demonstrated to have a pivotal role in the pathogenesis of rheumatoid arthritis, Castleman’s disease and Crohn’s disease exemplified by the use of an anti-IL-6 biological therapy. However, IL-6 is also associated with the autoimmune disease systemic sclerosis (SSc) and has been shown to be directly fibrotic. Elevated levels of IL-6 are found in SSc patients and this correlates with skin thickness, suggesting a causal effect. This review focuses on the role of IL-6 in SSc, a chronic autoimmune disease with fibrosis. In particular, we will examine the evidence base of the role of IL-6 in fibrosis in this condition, especially the downstream effector pathways. We will then argue why molecular targeting of IL-6 is a promising therapeutic target in this fibrosing disease...

(Excerpt) Read more at nature.com ...


TOPICS: Culture/Society; News/Current Events
KEYWORDS: arthritis; autoimmunedisease; castlemans; crohns; fibrosis; immunology; interleukin6; multiplesclerosis; systemicsclerosis
It's a FReebie. You may have to register.
1 posted on 05/08/2013 3:50:30 PM PDT by neverdem
[ Post Reply | Private Reply | View Replies]

To: neverdem

Pure B.S. I was the Senior product Manager for IL-3 and IL-6. Most interleukins (1-12) are highly toxic in doses needed to have an effect. I would highly doubt you will ever see medical use of IL-6. It was also studied for a supposed anti-tumor effect which did not exist.


2 posted on 05/08/2013 4:56:14 PM PDT by Doc Savage ("I've shot people I like a lot more,...for a lot less!" Raylan Givins)
[ Post Reply | Private Reply | To 1 | View Replies]

To: Doc Savage

They’re not talking about administering IL-6, but drugs to block its effects. Such might be effective and safe enough for some conditions.


3 posted on 05/08/2013 7:23:09 PM PDT by JohnBovenmyer (Obama been Liberal. Hope Change!)
[ Post Reply | Private Reply | To 2 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson